Liquid Biopsy Market Size to Reach USD 22.69 Billion by 2034

Liquid Biopsy Market Set to Transform Cancer Detection and Monitoring

The global liquid biopsy market is valued at USD 7.05 billion in 2025 and is projected to reach approximately USD 22.69 billion by 2034, growing at a compound annual growth rate (CAGR) of 13.91% during the forecast period. This market is gaining significant traction as a transformative solution in oncology, fueled by the rising incidence of cancer, growing demand for early and non-invasive diagnostic methods, and rapid advancements in genomic and molecular technologies.

🧬 Liquid Biopsy Market Overview – Key Insights for 2024

The global liquid biopsy market is gaining strong momentum, driven by rising demand for non-invasive cancer diagnostics and technological advancements. In 2024, North America led the market with a 45.59% revenue share. Next-generation sequencing (NGS) dominated the technology segment at 65.20%, while blood-based tests remained the most preferred sample type, contributing 67.59% of the market.

The clinical usage segment accounted for 72.17% of revenues, highlighting the growing reliance on liquid biopsy in patient care. Cell-free DNA (cfDNA) emerged as the leading biomarker, representing 47.87% of the market, and is expected to see further growth in the coming years. Kits and consumables made up 53.12% of product revenues, followed closely by test/services.

Lung cancer remained the top indication, contributing 32.10% of market share, with screening applications dominating at 39.27%. Together, these trends reflect a strong push toward precision oncology and early detection.

Key Growth Drivers of the Liquid Biopsy Market

The global liquid biopsy market is experiencing robust growth, primarily driven by the rising prevalence of cancer and growing awareness of non-invasive diagnostic solutions. According to the GLOBOCAN 2020 estimates from the International Agency for Research on Cancer, approximately 19.3 million new cancer cases and 10 million cancer-related deaths were reported worldwide in 2020. Among these, breast cancer emerged as the most commonly diagnosed type, with 2.3 million new cases, followed by lung, colorectal, and prostate cancers.

Cancer remains the second leading cause of death globally, as reported by the World Health Organization. This alarming burden is pushing demand for more efficient and less invasive diagnostic methods—making liquid biopsy an increasingly favored option.

Liquid biopsy offers multiple advantages over traditional tissue biopsies, including early cancer detection, low risk, cost-effectiveness, rapid results, and the ability to monitor tumor progression and assess prognosis. Furthermore, its capability to overcome tumor heterogeneity enhances its clinical value. These benefits are significantly contributing to the rising adoption of liquid biopsy across both developed and developing markets.

Read Also 🔖 – Floating Solar Market

Market Scope

🚀 Opportunity: Advancements in Precision Medicine and Biomarker Technologies

Ongoing innovations in circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles are significantly improving the accuracy and clinical value of liquid biopsy tests. These breakthroughs enhance the ability to detect tumor-specific alterations with high sensitivity and monitor treatment response and disease progression in real time.

As precision medicine gains traction, liquid biopsy offers a powerful tool for tailoring cancer therapies to an individual’s unique genetic profile—improving treatment effectiveness while minimizing side effects. With personalized oncology becoming a central focus in cancer care, pharmaceutical and diagnostic companies are increasingly investing in liquid biopsy technologies to accelerate the development of targeted, patient-specific therapies.

Liquid Biopsy Market – Key Players

• Bio-Rad Laboratories
• Biocept Inc.
• Guardant Health
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Laboratory Corporation of America Holdings
• MDxHealth SA
• QIAGEN N.V
• Thermo Fisher Scientific Inc.